As sales of appetite-suppressing drugs such as Ozempic and Mounjaro skyrocket, corporate America is grappling with the question: How does a less-hungry, less-impulse-prone consumer affect my business model?
Ozempic for weight loss is disrupting companies’ business model
As sales of appetite-suppressing drugs such as Ozempic and Mounjaro skyrocket, corporate America is grappling with the question: How does a less-hungry, less-impulse-prone consumer affect my business model?